Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Stevanato Group (STVN) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank put ...

Summary of Stevanato Group Conference Call Company Overview - **Company**: Stevanato Group (NYSE: STVN) - **Industry**: Pharmaceutical packaging and delivery systems - **Experience**: Over 70 years in the industry, with a focus on the pharmaceutical sector for the last 25 years [2][3] Core Business Segments - **Integrated Platform**: Stevanato Group offers an end-to-end value proposition for the biopharmaceutical industry, focusing on injection-related products [3][4] - **Product Offerings**: Includes traditional vials, syringes (including Nexa and Alba technologies), double chamber syringes, and cartridge-ready products [3][4][6] - **Market Position**: - Market leader in cartridges and vials - Second in syringes globally [5][6] Financial Performance - **Revenue Growth**: - Doubled revenue over the last five years despite challenges such as inventory stocking and foreign exchange issues [7] - Achieved over 40% of revenue from biologics in the first nine months of the year [16] - **Investment**: Raised $1.1 billion from the IPO in 2021, with significant reinvestment into R&D and capacity expansion [8][10] Market Dynamics - **Biopharmaceutical Growth**: The market is experiencing robust growth, particularly among top 25 global customers with rich pipelines in phases two and three [6][7] - **High-Value Products**: Increasing demand for high-value solutions, with a focus on biologics and auto-injectors [15][16] - **GLP-1 Drugs**: Expected to be a strong contributor to revenue, with a projected market share of around 30% for oral formulations in the medium term [46][47] Capacity and Production - **Capacity Expansion**: - Ongoing investments in facilities in Piombino Dese and Fisher, Indiana, with a total investment of $500 million expected to generate $500 million in revenue by 2028 [14][15] - Plans to increase capacity for cartridges and syringes, particularly in response to the growing demand for biologics [13][15] - **Normalization of Vial Orders**: Anticipated growth of 1%-2% for bulk vials and double-digit growth for easy-fill vials by 2026 [36][37] Strategic Focus - **Integrated Systems Strategy**: Aiming to provide a holistic solution for pharmaceutical companies by integrating various components of the supply chain [44][45] - **Client Relationships**: Emphasis on building long-term partnerships with clients to ensure a stable supply chain and meet evolving needs [9][11] Challenges and Outlook - **COVID-19 Impact**: Experienced both tailwinds and headwinds due to the pandemic, with a recovery expected in vial volumes [32][34] - **Biosimilar Market**: Anticipated growth in biosimilars, with similar economic opportunities as originator products [17][22] Engineering Segment - **Operational Upgrades**: Recent enhancements in the engineering division, including increased capacity and improved project management [48][50] - **Healthy Pipeline**: Positive outlook for new opportunities, although conversion to confirmed orders is slower than expected [51] This summary encapsulates the key points discussed during the Stevanato Group conference call, highlighting the company's strategic direction, market position, and financial performance.

Summary of Stevanato Group Conference Call Company Overview - **Company**: Stevanato Group (NYSE: STVN) - **Industry**: Pharmaceutical packaging and automation solutions - **Core Products**: Glass primary packaging components (vials, cartridges, syringes) and modular automated production machinery [1][2] Key Growth Drivers - **Market Position**: Stevanato is well-positioned to leverage growth in biologics, with a long track record of double-digit organic growth [4][5] - **Capital Expenditure**: Significant investments in new plants, including $500 million in Fishers, Indiana, expected to ramp up by 2028, and another plant in Italy [4][5] - **Customer Base**: Serves 23 of the 25 largest pharmaceutical companies, indicating strong demand and high barriers to entry due to capital and expertise requirements [5][6] Financial Performance - **Growth Outlook**: Anticipates mid to high single-digit growth in 2025, with normalization expected in 2026 [7][11] - **High-Value Solutions**: Revenue from high-value solutions reached approximately $520 million, with a 50% growth in Q3 [14][15] - **Profit Margins**: High-value products have gross profit margins of 40%-70%, compared to 15%-35% for non-high-value products, indicating a significant opportunity for margin expansion [18][23] Market Dynamics - **Destocking Effects**: The company has moved past destocking challenges and is seeing a recovery in demand, particularly for sterile vials and high-performance syringes [7][10] - **Competitive Landscape**: Opportunities to gain market share due to disruptions among competitors and the company's innovative product offerings [12][13] Policy and Regulatory Environment - **MFN and Reshoring**: Recent policy changes, including MFN (Most Favored Nation) pricing, are seen as positive for the company, providing more certainty and potential for increased demand [24][25] - **GLP-1 Market**: The company views the growth of the GLP-1 market as a tailwind, with expectations of increased demand for biologics and related packaging solutions [39][41] Engineering Segment - **Engineering Demand**: The engineering segment is currently experiencing timing issues but is expected to recover as new orders are confirmed [50][52] - **Automation Trends**: Increased automation in manufacturing is seen as a key advantage, particularly in developed markets like the U.S. [34][35] Future Outlook - **Long-Term Growth**: The company is optimistic about future growth driven by high-value solutions, increased capacity, and favorable market conditions [23][54] - **Biosimilars and Annex One**: The push towards biosimilars and compliance with Annex One regulations in Europe are expected to further enhance market opportunities [42][49] Conclusion - Stevanato Group is strategically positioned for growth in the pharmaceutical packaging industry, with significant investments in capacity and a strong focus on high-value products. The company is navigating current market challenges while preparing for future opportunities driven by policy changes and increasing demand for biologics.

Financial Performance - Revenue for Q3 2025 reached €303.2 million, a 9.1% increase from €277.9 million in Q3 2024[14] - Gross profit for Q3 2025 was €88.5 million, up 18.9% from €74.4 million in Q3 2024[14] - Operating profit for the nine months ended September 30, 2025, increased to €128.7 million, a 36.4% rise from €94.3 million in the same period of 2024[14] - Net profit for Q3 2025 was €36.1 million, compared to €30.0 million in Q3 2024, reflecting a 20.1% growth[14] - Basic earnings per share for Q3 2025 were €0.13, up from €0.11 in Q3 2024, indicating an 18.2% increase[14] - Total comprehensive income for Q3 2025 was €39.3 million, compared to a loss of €2.6 million in Q3 2024[16] - Profit before tax for the nine months ended September 30, 2025, increased to €123,344 thousand, up from €95,637 thousand in 2024, representing a growth of 29%[21] - Net cash flows from operating activities rose to €191,970 thousand, compared to €112,141 thousand in the same period of 2024, marking an increase of 71%[21] - Basic earnings per ordinary share for the nine months ended September 30, 2025, were €0.34, reflecting a 30.8% increase from €0.26 in 2024[182] Expenses and Costs - Research and development expenses for the nine months ended September 30, 2025, were €19.6 million, down from €26.1 million in the same period of 2024, a decrease of 25.5%[14] - Selling and marketing expenses for the nine months ended September 30, 2025, increased to €20.3 million from €19.0 million in the same period of 2024, a rise of 7.2%[14] - Total expenses for the nine months ended September 30, 2025, were EUR 113,030 thousand, slightly down from EUR 113,439 thousand in 2024[65] - Selling and marketing expenses rose to EUR 20,346 thousand for the nine months ended September 30, 2025, compared to EUR 18,950 thousand in 2024, reflecting increased personnel and marketing costs[65] - Total cost of sales for the nine months ended September 30, 2025, was EUR 602,823 thousand, compared to EUR 569,276 thousand in 2024, reflecting a 5.9% increase[62] Assets and Liabilities - Total assets increased to €2,414,007 thousand as of September 30, 2025, up from €2,328,819 thousand at December 31, 2024, representing a growth of 3.67%[18] - Total liabilities increased to €976,721 thousand at September 30, 2025, compared to €924,434 thousand at December 31, 2024, an increase of 5.66%[18] - Current assets increased slightly to €884,475 thousand as of September 30, 2025, from €879,901 thousand at December 31, 2024, reflecting a growth of 0.65%[18] - Cash and cash equivalents increased to €113,333 thousand at September 30, 2025, from €98,270 thousand at December 31, 2024, representing a growth of 15.3%[18] - Trade receivables decreased to €266,824 thousand at September 30, 2025, down from €295,951 thousand at December 31, 2024, a decline of 9.8%[18] - Total financial liabilities rose to EUR 453,349 thousand at September 30, 2025, from EUR 434,605 thousand at December 31, 2024, primarily due to increased bank loans[120] Market and Growth Outlook - The company anticipates continued growth driven by demand for its products and ongoing capacity expansion initiatives[10] - The total addressable market is estimated to exceed $13 billion in 2024, covering drug containment solutions, drug delivery systems, IVD solutions, and engineering[176] - The Group is expanding its global capacity, particularly in Italy and the United States, with commercial production of high-value syringes launched in 2023 and ready-to-use cartridge production expected to start in 2026[23] - The Group's global footprint allows it to sell products and provide services in approximately 70 countries worldwide, enhancing its market reach[23] Financial Risks and Management - The Group is exposed to financial risks including foreign currency exchange rates, liquidity, credit, and commodity price fluctuations, which could significantly impact financial performance[43] - The average foreign currency exchange rate for the US dollar was 1.1188 for the nine months ended September 30, 2025, compared to 1.0871 for the same period in 2024, indicating a depreciation of the Euro[46] - The Group is assessing the impact of the new Pillar Two income taxes legislation on its future financial performance, with potential exposure identified in China[80][79] Investments and Capital Expenditures - The Group's investment in property, plant, and equipment for the nine months ended September 30, 2025, was €174,409 thousand, a decrease from €213,718 thousand in 2024, down by 18%[21] - Capital expenditures related to ongoing infrastructure investments were approximately EUR 105 million, net of expected contributions from BARDA, which agreed to contribute up to approximately USD 95 million (EUR 80 million) for manufacturing capacity[89] - Property, plant, and equipment additions for the nine months ended September 30, 2025, were EUR 187,650 thousand, driven by new production lines in Fishers, Indiana, and Latina, Italy[87] Shareholder Information - The Group's equity interest in Medical Glass a.s. is 99.74%, with net profit attributable to non-controlling interests reported as of September 30, 2025[42] - The company has a Long Term Incentive Plan running from January 1, 2023 to December 31, 2027, divided into three vesting periods[138] - Share-based compensation expense recognized for the nine months ended September 30, 2025, was EUR 1,013 thousand, down from EUR 1,886 thousand in the same period of 2024[154]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 increased by 9% year over year to $303.2 million, driven by a 14% increase in the BDS segment, which offset a 19% decline in the engineering segment [12][15] - Adjusted EBITDA increased to €77.8 million, with an adjusted EBITDA margin improving by 280 basis points to 25.7% [15] - Net profit totaled $36.1 million, with diluted EPS of $0.13, while adjusted diluted EPS increased 17% to $0.14 [14][15] - Consolidated gross profit margin reached 29.2%, a 240 basis point increase, primarily due to a favorable mix of high-value solutions [13][15] Business Line Data and Key Metrics Changes - The BDS segment revenue rose 14% to €266.7 million, with high-value solutions growing by 47% and representing 55% of segment revenue [15][16] - Revenue from the engineering segment decreased by 19% to €36.4 million, driven by lower revenue from glass conversion and assembly lines [17] - Gross profit margin for the BDS segment increased by 400 basis points to 32%, while the engineering segment's gross profit margin declined to 10.4% [16][17] Market Data and Key Metrics Changes - The company noted strong demand for high-value solutions, particularly in the injectable biologics market, which is expected to continue driving growth [6][7] - The ongoing recovery in vial demand is contributing positively, with expectations of returning to pre-pandemic levels for bulk vials by 2026 [58] Company Strategy and Development Direction - The long-term strategy focuses on meeting the demands of high-growth markets such as injectable biologics, emphasizing premium containment and delivery solutions [6][7] - The company is investing in capacity expansion to support the rising demand for high-value products, with significant capital projects underway in Fishers and Latina [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting 2025 guidance despite headwinds from foreign currency and tariffs, citing strong momentum from high-value solutions [4][19] - The company remains optimistic about the long-term demand landscape for manufacturing technologies, particularly as customers invest in U.S. manufacturing operations [9][19] Other Important Information - The company received the COVADIS Silver Medal, placing it in the top 15% of companies assessed globally, reflecting its commitment to sustainability and ESG practices [11] Q&A Session Summary Question: Can you provide more details on the $10 million outperformance in the quarter? - The $10 million outperformance was due to an acceleration of product shipments in the BDS segment, accommodating customer supply chain needs [23] Question: What drove the strong growth in the quarter, and how does the trajectory look going into next year? - Strong demand for high-performance syringes, particularly Nexa, and recovery in Easyfill vials contributed to growth, with expectations for continued robust demand [24][25] Question: Can you update on the margin improvement in Fishers and Latina? - Latina is approaching normalized gross profit margins, while Fishers is still improving but has not yet reached positive margins [27][28] Question: What is the timeline for the engineering segment to return to growth? - The engineering segment is experiencing delays in order conversion, but there is a healthy pipeline and positive feedback from customers, indicating potential for future growth [29][30] Question: How significant are biosimilars to the company's growth strategy? - Biosimilars are expected to contribute to revenue growth, with the company actively engaged in developing products for this market [34][36] Question: What is the outlook for high-value solutions in Q4? - Guidance for Q4 implies a range of 40-41% for high-value solutions, driven by backlog and recent order acceleration [72]

Core Insights - Stevanato Group reported quarterly earnings of $0.16 per share, exceeding the Zacks Consensus Estimate of $0.14 per share, and showing an increase from $0.13 per share a year ago, resulting in an earnings surprise of +14.29% [1] - The company achieved revenues of $354.42 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.54% and increasing from $305.42 million year-over-year [2] - Stevanato has outperformed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times in the same period [2] Earnings Outlook - The sustainability of Stevanato's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - The current consensus EPS estimate for the upcoming quarter is $0.22 on revenues of $403.73 million, and for the current fiscal year, it is $0.58 on revenues of $1.36 billion [7] Industry Context - The Medical - Drugs industry, to which Stevanato belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Stevanato's stock performance [5]

Financial Performance - Revenue grew by 9% year-over-year (11% at constant currency) in Q3 2025, driven by strong performance in the Biopharmaceutical and Diagnostic Solutions (BDS) segment[12] - High-Value Solutions (HVS) revenue increased by 47% year-over-year, reaching €147.9 million, representing 49% of total revenue[28] - Adjusted EBITDA increased to €77.8 million, with an adjusted EBITDA margin increase of 280 bps to 25.7%[29] - The company maintains its fiscal year 2025 revenue guidance at €1.160 billion - €1.190 billion, implying a growth of 5% to 8%[39] Segment Analysis - The BDS segment revenue increased by 14% (17% at constant currency), with a gross profit margin increase of 400 bps to 32.0%[32] - The Engineering segment revenue decreased by 19% to €36.4 million, with a gross profit margin decrease to 10.4%[34] Capacity Expansion and Investments - The company is expanding capacity for PFS and EZ-fill® cartridges in Latina, Italy, with commercial production expected to launch at the end of FY26[22] - Capital expenditures (CAPEX) for Q3 2025 were €54.9 million[36]

Core Insights - The article compares Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN) to identify which stock presents a better undervalued investment opportunity [1] Valuation Metrics - Sandoz Group AG has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Stevanato Group has a Zacks Rank of 3 (Hold) [3] - The forward P/E ratio for SDZNY is 20.24, significantly lower than STVN's forward P/E of 43.25, suggesting SDZNY may be undervalued [5] - SDZNY has a PEG ratio of 1.12, compared to STVN's PEG ratio of 2.46, indicating SDZNY's earnings growth is more favorable relative to its valuation [5] - The P/B ratio for SDZNY is 3.29, while STVN's P/B ratio is 4.76, further supporting the notion that SDZNY is more attractively priced [6] - Based on these metrics, SDZNY has a Value grade of B, while STVN has a Value grade of C, indicating a stronger value proposition for SDZNY [6] Earnings Outlook - SDZNY is noted for its improving earnings outlook, which enhances its attractiveness as a value investment compared to STVN [7]

Core Insights - Stevanato Group S.p.A. will participate in two upcoming investor conferences, indicating its active engagement with investors and the market [1][9] - The company is a leading global provider of drug containment, drug delivery, and diagnostic solutions, serving the pharmaceutical, biotechnology, and life sciences industries [3][8] Upcoming Events - The company will attend the 7th Annual Wolfe Research Healthcare Conference in New York City on November 17, 2025, at 8:40 a.m. ET [5] - It will also participate in the Jefferies Global Healthcare Conference in London on November 19, 2025, at 11:00 a.m. GMT [5] Company Overview - Founded in 1949, Stevanato Group offers an integrated portfolio of products, processes, and services that address customer needs across the entire drug life cycle [3] - The company's core capabilities include scientific research and development, technical innovation, and engineering excellence, which are essential for providing value-added solutions to clients [3]

Core Points - Stevanato Group S.p.A. will report its financial results for the third quarter of 2025 on November 6, 2025, at 6:30 a.m. (ET) [1] - A conference call and webcast will be held on the same day at 8:30 a.m. (ET) to discuss the financial results, with a slide presentation available on the company's Investor Relations page [2] - Participants are encouraged to pre-register for the conference call to gain immediate access [3] Company Overview - Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries [4] - The company offers an integrated portfolio of products, processes, and services that address customer needs across the entire drug life cycle [4] - Stevanato Group emphasizes its core capabilities in scientific research and development, technical innovation, and engineering excellence [4]